Corium International Inc. (NASDAQ:CORI) – Equities researchers at Jefferies Group issued their Q3 2017 earnings per share estimates for shares of Corium International in a note issued to investors on Wednesday. Jefferies Group analyst D. Steinberg expects that the firm will post earnings per share of ($0.43) for the quarter. Jefferies Group also issued estimates for Corium International’s Q4 2017 earnings at ($0.46) EPS.
Several other research firms also recently issued reports on CORI. FBR & Co set a $18.00 price target on shares of Corium International and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research downgraded shares of Corium International from a “hold” rating to a “sell” rating in a research note on Tuesday, October 11th. Leerink Swann set a $16.00 price target on shares of Corium International and gave the stock a “buy” rating in a research note on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Corium International in a research note on Monday, September 26th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $12.25.
Shares of Corium International (NASDAQ:CORI) opened at 4.70 on Thursday. The stock’s market capitalization is $104.37 million. The stock has a 50 day moving average of $5.04 and a 200-day moving average of $4.71. Corium International has a one year low of $3.14 and a one year high of $9.93.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LLC raised its position in shares of Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock valued at $5,888,000 after buying an additional 192,786 shares in the last quarter. Opaleye Management Inc. raised its position in Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares during the period. Finally, Paloma Partners Management Co acquired a new position in Corium International during the second quarter valued at approximately $152,000. 88.35% of the stock is owned by institutional investors.
About Corium International